Over the past five years, Valeant Pharmacueticals (NYSE:VRX) stock is up 856%, absolutely smashing the returns delivered by the market. And the company has recently made waves by teaming up with activist investor Bill Ackman of Pershing Square to take over Allergan (UNKNOWN:AGN.DL), the specialty pharma company famous for Botox. 

In the following video, Motley Fool analysts Michael Douglass and Brendan Mathews discuss the three things investors should be watching for in Valeant. Brendan notes that investors should keep a close eye on Valeant's organic growth, projected cash earnings per share, and achievement of synergies from past acquisitions, especially the Bausch + Lomb purchase. 

Brendan Mathews owns shares of Valeant Pharmaceuticals. Michael Douglass has no position in any stocks mentioned. The Motley Fool owns and recommends shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.